The controversial anti-obestity drug rimonabant, marketed as Acomplia, has been approved for National Health Service (NHS) use in the England and Wales. The National Institute for Healthcare and Clinical Excellence (NICE) has approved use of this diet drug in people who are clinically obese or people who are seriously overweight with complications such as diabetes.

The drug, made by Sanofi-Aventis, is approved for sale in Britain and elsewhere in the European Union but was rejected by a U.S. Food and Drug Administration panel in June 2007 because of concerns the drug increases the risk of depression and suicidal thoughts

Eating a big breakfast consisting of high carbohydrates and protein the first thing in morning and then following a low-carb, low-calorie diet the rest of the day helps maintain a healthy weight loss, the authors of a new study recommend.

Researchers from the Hospital de Clinicas in Caracas, Venezuela say eating a big breakfast packed with protein and carbohydrates helps cut cravings for sweet or starchy foods, as well as boosting the metabolism. Breakfast has long been touted as the most important meal of the day, particularly for those who want to lose weight

A fruit-flavoured placebo pill developed to trick children into thinking they have had medical treatment will soon be launched in Britain despite stark criticism from child experts.

The sugar pills named Obecalp-placebo spelled backwards-are already on sale in the U.S. as over-the-counter medication, costing $6 for a bottle of 50

People suffering from type 2 diabetes are at a greater risk of suffering from depression too, a new study has found, suggesting the two may go hand in hand.

In a study in the latest Journal of the American Medical Association, doctors from Johns Hopkins University found patients with type 2 diabetes are 54 percent more likely to become depressed, and patients diagnosed with depression are 42 percent more likely to develop diabetes

Consumption of foods rich in omega-3 fatty acids can reduce the risk of age-related macular degeneration, a survey of published research suggests.

University of Melbourne researchers reached this conclusion after reviewing nine published studies that included a total of 88,974 participants, including 3,203 people with AMD